See the DrugPatentWatch profile for Qulipta
Qulipta (atogepant) received FDA approval on September 27, 2021, for the preventive treatment of episodic migraine in adults [1].
What is Qulipta used for?
Qulipta is prescribed to reduce the number of monthly migraine days in individuals experiencing episodic migraine [1].
How does Qulipta work?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a neurotransmitter that plays a role in migraine pathophysiology. By blocking the CGRP receptor, Qulipta helps to prevent the occurrence of migraines.
What are the common side effects of Qulipta?
The most frequently reported side effects of Qulipta include upper respiratory infection, nausea, and diarrhea [1].
When does Qulipta's patent expire?
Information regarding the specific patent expiry dates for Qulipta is available through resources like DrugPatentWatch.com [2]. Patent protection is crucial for pharmaceutical companies as it provides a period of market exclusivity.
Who manufactures Qulipta?
AbbVie Inc. manufactures Qulipta [1].
How does Qulipta compare to other migraine preventives?
Qulipta belongs to a class of drugs known as oral CGRP antagonists, which offer an alternative to older preventive treatments like beta-blockers, antidepressants, and anticonvulsants. Unlike CGRP monoclonal antibodies, which are administered via injection, Qulipta is taken orally [1].
What is the dosage for Qulipta?
Qulipta is available in 10 mg, 25 mg, 50 mg, and 60 mg extended-release tablets. The recommended dosage is typically 60 mg once daily [1].
Are there any Qulipta alternatives?
Beyond oral CGRP antagonists, other preventive migraine treatments include CGRP monoclonal antibodies (injectables), oral medications such as certain anticonvulsants (e.g., topiramate), beta-blockers (e.g., propranolol), and some antidepressants (e.g., amitriptyline) [3].
What clinical trials led to Qulipta's approval?
Qulipta's approval was based on data from two Phase 3 clinical trials, PROGRESS and PROMISE-2, which demonstrated its efficacy in reducing monthly migraine days in patients with episodic migraine [1].
What are the risks associated with Qulipta?
While generally well-tolerated, potential risks associated with Qulipta include hypersensitivity reactions [1]. Patients should discuss any concerns with their healthcare provider.
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-safety-and-milestones-september-2021
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360202